MSK Research Highlights New Drug Combinations for Advanced Renal Cell Carcinoma and Follicular Lymphoma

Memorial Sloan Kettering Cancer Center has highlighted new research findings, including a study published in The Lancet demonstrating that a novel drug combination significantly improves survival in patients with advanced clear cell renal cell carcinoma (ccRCC) after immune checkpoint inhibitor treatment. Additionally, a separate study published in Lancet Hematology shows that a three-drug, chemotherapy-free combination is effective in nearly all newly diagnosed patients with follicular lymphoma, producing deep and durable remissions.